Adepitan A Owosho1, Cherry L Estilo2, Joseph M Huryn3, SaeHee K Yom4. 1. Oral/Dental Oncology Research Fellow, Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 2. Attending, Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 3. Chief Attending, Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 4. Assistant Attending, Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: Kims2@mskcc.org.
Abstract
OBJECTIVE: Very few studies have evaluated the efficacy of pentoxifylline and tocopherol (PENT-E) in the management of medication-related osteonecrosis of the jaw (MRONJ), although some studies have shown the therapeutic and prophylactic benefit of PENT-E in the management of osteoradionecrosis. We report the outcomes of MRONJ managed with PENT-E in patients with metastatic bone disease or multiple myeloma. STUDY DESIGN: Seven patients diagnosed with established cases of refractory MRONJ caused by antiresorptive medications for the management of metastatic bone tumors or multiple myeloma were administered PENT-E for a mean period of 16.8 months (range 3-48 months). RESULTS: At the latest follow-up visit, all patients demonstrated relief of symptoms. There was radiographic evidence of new bone fill of prior radiolucent defect in all patients. Two patients had resolution of exposed bone, two patients had partial resolution, one patient had no change in exposed bone, and one patient with three sites of exposed bone before starting PENT-E had resolution in one site, partial resolution in another site, and no change in the third site. PENT-E was well tolerated in all patients. CONCLUSIONS: Our case series demonstrated that PENT-E was well tolerated and may be an effective adjunct in the management of MRONJ.
OBJECTIVE: Very few studies have evaluated the efficacy of pentoxifylline and tocopherol (PENT-E) in the management of medication-related osteonecrosis of the jaw (MRONJ), although some studies have shown the therapeutic and prophylactic benefit of PENT-E in the management of osteoradionecrosis. We report the outcomes of MRONJ managed with PENT-E in patients with metastatic bone disease or multiple myeloma. STUDY DESIGN: Seven patients diagnosed with established cases of refractory MRONJ caused by antiresorptive medications for the management of metastatic bone tumors or multiple myeloma were administered PENT-E for a mean period of 16.8 months (range 3-48 months). RESULTS: At the latest follow-up visit, all patients demonstrated relief of symptoms. There was radiographic evidence of new bone fill of prior radiolucent defect in all patients. Two patients had resolution of exposed bone, two patients had partial resolution, one patient had no change in exposed bone, and one patient with three sites of exposed bone before starting PENT-E had resolution in one site, partial resolution in another site, and no change in the third site. PENT-E was well tolerated in all patients. CONCLUSIONS: Our case series demonstrated that PENT-E was well tolerated and may be an effective adjunct in the management of MRONJ.
Authors: Matthew S Epstein; Fredrick W Wicknick; Joel B Epstein; James R Berenson; Meir Gorsky Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2010-11
Authors: John J Freiberger; Rebecca Padilla-Burgos; Austin H Chhoeu; Kevin H Kraft; Otto Boneta; R E Moon; C A Piantadosi Journal: J Oral Maxillofac Surg Date: 2007-07 Impact factor: 1.895
Authors: F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey Journal: Ann Oncol Date: 2011-10-10 Impact factor: 32.976
Authors: Olga Di Fede; Federica Canepa; Vera Panzarella; Rodolfo Mauceri; Carmine Del Gaizo; Alberto Bedogni; Vittorio Fusco; Pietro Tozzo; Giuseppe Pizzo; Giuseppina Campisi; Antonio Galvano Journal: Int J Environ Res Public Health Date: 2021-08-10 Impact factor: 3.390
Authors: Lorenz Schubert; Guenter Russmueller; Heimo Lagler; Selma Tobudic; Elisabeth Heindel; Michael Kundi; Christoph Steininger Journal: Support Care Cancer Date: 2021-06-30 Impact factor: 3.603